Flagship Pioneering, an American life sciences venture capital (VC) company based in Cambridge, Massachusetts that invests in biotechnology, life sciences, health and sustainability companies, has announced its expansion into the Asia-Pacific (APAC) region, with the opening of a regional hub in Singapore.

This follows the company's expansion into the UK earlier this year. André Andonian has joined Flagship as Chair of Asia Pacific and Senior Advisor to lead Flagship's presence in the region with a focus on furthering the global reach and impact of Flagship and its companies. 

Flagship Pioneering creates and builds platform companies designed to generate multiple products that secure a healthier and more sustainable future. For more than 20 years, Flagship has originated and fostered more than 100 scientific ventures, resulting in more than $90 billion in aggregate value. The current Flagship ecosystem comprises 43 impactful companies spanning human therapeutics, agriculture, and nutrition. 

The global expansion of Flagship's presence into the APAC region follows the opening of the company's office in London earlier this year. Later this month, Flagship will co-host an event in partnership with the UK Government's Office for Life Sciences, bringing together top leaders from industry, government, and academia, with a focus on breakthrough innovation.

The current Flagship ecosystem comprises 43 companies, including Denali Therapeutics, Foghorn Therapeutics, Generate:Biomedicines, Inari, Indigo Agriculture, Moderna, Omega Therapeutics, Sana Biotechnology, Seres Therapeutics and Tessera Therapeutics.